Frédéric Guerard has been appointed CEO of Graybug Vision. Guerard joins the Redwood City, CA-based eye diseases drug developer from Novartis (NYSE: [[ticker:NVS]]), where he had several roles, most recently worldwide business franchise head of ophthalmology. Graybug’s lead drug candidate, GB-102, is being prepared for Phase 2 studies testing it as a treatment for the “wet” form of age-related macular degeneration.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
